Poseida Therapeutics Inc
(PSTX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Sales | 71,748 | 25,973 | 28,142 | 24,995 | 9,352 |
| Gross Profit | 71,748 | 25,973 | 28,142 | 24,995 | 9,352 |
| Operating Expenses | 52,006 | 57,729 | 52,719 | 50,906 | 45,574 |
| Operating Income | 19,742 | -31,756 | -24,577 | -25,911 | -36,222 |
| Interest Expense | 2,295 | 2,259 | 2,253 | 2,266 | 2,236 |
| Other Income | 2,831 | 2,644 | 2,556 | 2,828 | 6,787 |
| Pre-tax Income | 20,278 | -31,371 | -24,274 | -25,349 | -31,671 |
| Income Tax | 43 | N/A | N/A | N/A | 107 |
| Net Income Continuous | 20,235 | -31,371 | -24,274 | -25,349 | -31,778 |
| Net Income | $20,235 | $-31,371 | $-24,274 | $-25,349 | $-31,778 |
| EPS Basic Total Ops | 0.21 | -0.32 | -0.25 | -0.25 | -0.35 |
| EPS Basic Continuous Ops | 0.21 | -0.32 | -0.25 | -0.26 | -0.35 |
| EPS Diluted Total Ops | 0.21 | -0.32 | -0.25 | -0.25 | -0.35 |
| EPS Diluted Continuous Ops | 0.21 | -0.32 | -0.25 | -0.26 | -0.35 |
| EPS Diluted Before Non-Recurring Items | 0.21 | -0.32 | -0.25 | -0.27 | -0.35 |
| EBITDA(a) | $19,350 | $-31,767 | $-24,824 | $-26,410 | $-36,538 |